Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Agomab Therapeutics N.V.
BioCentury | Jul 12, 2024
Management Tracks
J.P. Morgan adds Joseph Siletto as managing partner
Plus: Fresenius and NS Pharma name new presidents, and updates from The Francis Crick Institute, CIRM, Nuvalent and more
BioCentury | Jul 10, 2024
Management Tracks
Pfizer seeking successor as Dolsten prepares to step down from R&D role
Plus: Lexicon, Pathios and Xeris name new CEOs, and updates from Jazz, AgomAb, VectorY, eTheRNA and more
BioCentury | Nov 30, 2023
Management Tracks
Kerr, Zimmermann leaving Generation Bio amid restructuring, headcount cuts
Plus: Sáez becomes Agomab’s chief development officer and updates from Forest Road, PDS, enGene and Pyxis
BioCentury | Oct 12, 2023
Politics, Policy & Law
Oct. 11 Quick Takes: European Parliament proposes amendments to pharma legislation
Plus: Early stop for Novo’s kidney outcomes study of semaglutide; Agomab raises $100M series B; and updates from MinervaX, FDA, ARPA-H, Tempest, Kanvas-Federation Bio
BioCentury | Jul 14, 2022
Finance
July 13 Quick Takes: Pliant raises $200M on back of positive data; CytomX restructuring
Plus ContraFect tumbles on exebacase setback, and updates from AgomAb, Xilis, and more
BioCentury | Oct 1, 2021
Finance
Sept. 30 Quick Takes: Advent closes €86M second fund
Data for Sanofi’s anti-OX40 mAb, plus TrialSpark’s $156M series C, Minerva’s next step toward schizophrenia submission and more
BioCentury | Jul 2, 2021
Management Tracks
McKinsey alums Santos da Silva, Bodenstedt join MoonLake; plus Takeda, Plexxikon, Solid, EQRx, Cardior and more
Two months after Merck KGaA (Xetra:MRK) teamed up with BVF Partners to launch MoonLake Immunotherapeutics AG, the newco has hired McKinsey veterans Jorge Santos da Silva as CEO and
BioCentury | Mar 11, 2021
Emerging Company Profile
AgomAb: antibodies driving tissue regeneration and recovery
Emerging Company Profile: argenx spinout AgomAb raises $74M series B to complete clinical POC for lead mAb and grow pipeline
BioCentury | Feb 11, 2021
Finance
Belgium’s V-Bio looking for bigger bets in and out of its home country with
Firm seeks to groom management teams returning to start-ups
Items per page:
1 - 10 of 10